Back to Search Start Over

Chapter One: Transcriptional regulation of natural killer cell development and maturation.

Authors :
Kee, Barbara L.
Morman, Rosmary E.
Sun, Mengxi
Source :
Advances in Immunology; 2020, Vol. 146, p1-28, 28p
Publication Year :
2020

Abstract

Natural killer cells are lymphocytes that respond rapidly to intracellular pathogens or cancer/stressed cells by producing pro-inflammatory cytokines or chemokines and by killing target cells through direct cytolysis. NK cells are distinct from B and T lymphocytes in that they become activated through a series of broadly expressed germ line encoded activating and inhibitory receptors or through the actions of inflammatory cytokines. They are the founding member of the innate lymphoid cell family, which mirror the functions of T lymphocytes, with NK cells being the innate counterpart to CD8 T lymphocytes. Despite the functional relationship between NK cells and CD8 T cells, the mechanisms controlling their specification, differentiation and maturation are distinct, with NK cells emerging from multipotent lymphoid progenitors in the bone marrow under the control of a unique transcriptional program. Over the past few years, substantial progress has been made in understanding the developmental pathways and the factors involved in generating mature and functional NK cells. NK cells have immense therapeutic potential and understanding how to acquire large numbers of functional cells and how to endow them with potent activity to control hematopoietic and non-hematopoietic malignancies and autoimmunity is a major clinical goal. In this review, we examine basic aspects of conventional NK cell development in mice and humans and discuss multiple transcription factors that are known to guide the development of these cells. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00652776
Volume :
146
Database :
Supplemental Index
Journal :
Advances in Immunology
Publication Type :
Academic Journal
Accession number :
142864176
Full Text :
https://doi.org/10.1016/bs.ai.2020.01.001